Vaccine ConfidenceVACCINE-WESTNCT07878442
Tailored Vaccine Messaging for Parents/Caregivers of Adolescents
A study testing Tailored Vaccine Messaging and Standard Vaccine Message in people with Vaccine Confidence and Adolescent Vaccination, run by University of Utah at 1 site in United States.
Trial summary
his study will evaluate whether tailored vaccine messaging improves vaccination-related outcomes among parents and caregivers of adolescents. Participants will complete a baseline electronic survey and will then be randomly assigned to receive either a tailored vaccine message based on insurance status or a standard… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Vaccine Confidence, Adolescent Vaccination, Vaccine Uptake
- What is being tested?
- Tailored Vaccine Messaging and Standard Vaccine Message
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,000 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2026to Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 18 and older
- Parents/caregivers (P/C) of children/teens (C/A) aged 9 to <18 years old, including those with public insurance/uninsured or private insurance
- Young adults (YAs) aged 18-26 residing in states west of the Mississippi River
Who cannot join
- Anyone not meeting the inclusion criteria
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
Kaila Christini, MS, MsPH, 801-581-6419, Kaila.Christini@hci.utah.edu
Deanna Kepka, PhD, MPH
About this study
Official title: Assessment of Adolescent and Young Adult Vaccine Confidence and Missed Opportunities for Vaccination in the Mountain West (VACCINE CONFIDENCE - WEST): A Randomized Tailored Vaccine Messaging Intervention
his study will evaluate whether tailored vaccine messaging improves vaccination-related outcomes among parents and caregivers of adolescents. Participants will complete a baseline electronic survey and will then be randomly assigned to receive either a tailored vaccine message based on insurance status or a standard vaccine message delivered by SMS text message. Approximately four weeks after receiving the intervention message, participants will complete a follow-up electronic survey assessing vaccination behaviors, vaccination intentions, vaccine confidence, perceived barriers to adolescent vaccination, and perceptions of the intervention message.
Read the detailed description
This randomized intervention study will evaluate the effectiveness of tailored vaccine messaging among parents and caregivers of adolescents. Participants will complete a baseline electronic survey assessing sociodemographic and geographic characteristics, vaccination behaviors, vaccine confidence, vaccine hesitancy, perceived barriers to vaccination, vaccine knowledge, and related vaccine perceptions.
Following completion of the baseline survey, participants will be randomized in a 1:1 ratio to receive either tailored vaccine messaging based on insurance status (public insurance/uninsured versus private insurance) or a standard vaccine message. Intervention messages will be delivered via SMS text messaging.
Approximately four weeks after intervention delivery, participants will complete a follow-up electronic survey assessing vaccination behaviors, vaccination intentions, vaccine confidence, perceived barriers to adolescent vaccination, and perceptions of the intervention message.
The study will also collect available intervention process measures, which may include successful message delivery, message receipt and/or opening when available, timing of message delivery, elapsed time between intervention delivery and follow-up survey completion, and other available messaging metadata. These measures will be used to characterize intervention implementation and participant engagement and to inform future messaging interventions.
- Conditions
- Vaccine Confidence, Adolescent Vaccination, Vaccine Uptake
- Being tested
- Tailored Vaccine Messaging, Standard Vaccine Message
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tailored Vaccine MessagingBehavioural
SMS text message providing vaccine-related information and messaging tailored according to participant insurance status.
Participants are randomized 1:1 to this intervention group following completion of the baseline survey.
Standard Vaccine MessageBehavioural
SMS text message providing standardized vaccine-related information and messaging without tailoring based on insurance status.
Intervention Assignment: Participants are randomized 1:1 to this comparison group following completion of the baseline survey.
| Study group | Role | What they receive |
|---|---|---|
| Tailored Messaging Group | Experimental | Participants will receive a vaccine message tailored according to insurance status (public insurance/uninsured versus private insurance) following completion of the baseline survey. Receives: Behavioral: Tailored Vaccine Messaging |
| Standard Messaging Group | Active comparator | Participants will receive a standard vaccine message following completion of the baseline survey. Receives: Behavioral: Standard Vaccine Message |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in vaccination intentions
Change in participant-reported intention to obtain recommended adolescent vaccinations from baseline to four-week follow-up, comparing participants receiving tailored vaccine messaging with those receiving standard vaccine messaging.
Measured: Baseline to approximately 4 weeks after intervention message delivery.
Change in vaccine confidence
Change in participant-reported vaccine confidence from baseline to four-week follow-up, comparing participants receiving tailored vaccine messaging with those receiving standard vaccine messaging.
Measured: Baseline to approximately 4 weeks after intervention message delivery.
Secondary outcomes (1)
Self-reported vaccination behavior
Change in participant-reported adolescent vaccination behavior from baseline to four-week follow-up, comparing participants receiving tailored vaccine messaging with those receiving standard vaccine messaging.
Measured: Baseline to approximately 4 weeks after intervention message delivery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2026
- Study startOct 2026 (estimated)
- Primary completionFeb 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vaccine ConfidenceStudies of the same condition, open and under way.
- More trials run by University of UtahThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will complete a baseline electronic survey and then be randomized 1:1 to receive either tailored vaccine messaging based on insurance status or a standard vaccine message.
- Masking
- None (open label)
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Collaborators
- Merck & Co., Inc.; Huntsman Cancer Institute's Intermountain West HPV Vaccination Coalition.
- Responsible party
- Sponsor
- Investigators
- Deanna Kepka, PhD, MPH, Principal investigator, Huntsman Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07878442
- Sponsor's protocol ID
- 206720
- Other IDs
- 10066664
- Acronym
- VACCINE-WEST
- Status last verified
- Oct 2026
- First submitted
- 9 Oct 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Adolescent and Young Adult Vaccine Confidence and Missed Opportunities for Vaccination in the Mountain West (VACCINE CONFIDENCE - WEST): A Randomized Tailored Vaccine Messaging Intervention
- ClinicalTrials.gov ID
- NCT07878442
- Acronym / sponsor ID
- VACCINE-WEST / 206720
- Conditions
- Vaccine Confidence, Adolescent Vaccination, Vaccine Uptake
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Collaborators
- Merck & Co., Inc.; Huntsman Cancer Institute's Intermountain West HPV Vaccination Coalition.
- Study start
- Oct 2026 (estimated)
- Primary completion
- Feb 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 16 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
his study will evaluate whether tailored vaccine messaging improves vaccination-related outcomes among parents and caregivers of adolescents. Participants will complete a baseline electronic survey and will then be randomly assigned to receive either a tailored vaccine message based on insurance status or a standard vaccine message delivered by SMS text message. Approximately four weeks after receiving the intervention message, participants will complete a follow-up electronic survey assessing vaccination behaviors, vaccination intentions, vaccine confidence, perceived barriers to adolescent vaccination, and perceptions of the intervention message.
Detailed description
This randomized intervention study will evaluate the effectiveness of tailored vaccine messaging among parents and caregivers of adolescents. Participants will complete a baseline electronic survey assessing sociodemographic and geographic characteristics, vaccination behaviors, vaccine confidence, vaccine hesitancy, perceived barriers to vaccination, vaccine knowledge, and related vaccine perceptions.
Following completion of the baseline survey, participants will be randomized in a 1:1 ratio to receive either tailored vaccine messaging based on insurance status (public insurance/uninsured versus private insurance) or a standard vaccine message. Intervention messages will be delivered via SMS text messaging.
Approximately four weeks after intervention delivery, participants will complete a follow-up electronic survey assessing vaccination behaviors, vaccination intentions, vaccine confidence, perceived barriers to adolescent vaccination, and perceptions of the intervention message.
The study will also collect available intervention process measures, which may include successful message delivery, message receipt and/or opening when available, timing of message delivery, elapsed time between intervention delivery and follow-up survey completion, and other available messaging metadata. These measures will be used to characterize intervention implementation and participant engagement and to inform future messaging interventions.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants will complete a baseline electronic survey and then be randomized 1:1 to receive either tailored vaccine messaging based on insurance status or a standard vaccine message.
| Arm | Type | Receives |
|---|---|---|
| Tailored Messaging Group | Experimental | Behavioral: Tailored Vaccine MessagingParticipants will receive a vaccine message tailored according to insurance status (public insurance/uninsured versus private insurance) following completion of the baseline survey. |
| Standard Messaging Group | Active comparator | Behavioral: Standard Vaccine MessageParticipants will receive a standard vaccine message following completion of the baseline survey. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged 18 and older
- Parents/caregivers (P/C) of children/teens (C/A) aged 9 to <18 years old, including those with public insurance/uninsured or private insurance
- Young adults (YAs) aged 18-26 residing in states west of the Mississippi River
Key exclusion criteria (1 listed)
- Anyone not meeting the inclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tailored Vaccine MessagingSMS text message providing vaccine-related information and messaging tailored according to participant insurance status. Participants are randomized 1:1 to this intervention group following completion of the baseline survey. | Behavioural | Tailored Messaging Group |
| Standard Vaccine MessageSMS text message providing standardized vaccine-related information and messaging without tailoring based on insurance status. Intervention Assignment: Participants are randomized 1:1 to this comparison group following completion of the baseline survey. | Behavioural | Standard Messaging Group |
Primary outcome
Change in vaccination intentions
Time frame: Baseline to approximately 4 weeks after intervention message delivery.
Change in participant-reported intention to obtain recommended adolescent vaccinations from baseline to four-week follow-up, comparing participants receiving tailored vaccine messaging with those receiving standard vaccine messaging.
Change in vaccine confidence
Time frame: Baseline to approximately 4 weeks after intervention message delivery.
Change in participant-reported vaccine confidence from baseline to four-week follow-up, comparing participants receiving tailored vaccine messaging with those receiving standard vaccine messaging.
1 secondary outcome
Self-reported vaccination behavior
Time frame: Baseline to approximately 4 weeks after intervention message delivery.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Deanna Kepka, PhD, MPH principal investigator
Huntsman Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tailored Vaccine Messaging and Standard Vaccine Message in people with Vaccine Confidence and Adolescent Vaccination, run by University of Utah at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kaila Christini, MS, MsPH (801-581-6419, Kaila.Christini@hci.utah.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in vaccination intentions (time frame: Baseline to approximately 4 weeks after intervention message delivery.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026; AzTrials last refreshed its copy on 8 Nov 2026.